pISSN 1226-6051
eISSN 2508-786X

Table. 1.

Table. 1.

Baseline characteristics of included studies

Study name Country Study design Intervention Comparison participants number Age, years [mean±SD, mmHg] Baseline IOP [mean±SD, mmHg] Conditions
intervention Control Total Intervention Control Intervention Control
Aihara 201726) Japan RCT BTFC DTFC 92 97 189 62.5±11.9 64.1±12.4 17.4±2.1 17.3±1.8 OAG, OHT
Fechtner 201627) USA RCT BBFC + PGA vehicle + PGA 88 94 182 65.5±9.4 64.7±9.6 24.5±0.3 24.3±0.3 OAG, OHT
MICHAUD et al. 200128) USA RCT brinzolamide + timolol dorzolamide + timolol 118 123 241 N/A N/A 25.5±1.9 25.8±2.2 POAG, OHT
Yoshikawa 201429) Japan RCT brinzolamide/timolol timolol 150 151 301 61±13.7 62±12.5 20.8±2.6 20.8±2.5 POAG, OHT
Aung 201430) Multi-nations RCT BBFC brinzolamide or brimonidine 193 192
175
560 64.9±12.2 64.1±11.2
64.3±11.6
27.0±0.18* 27.0±0.18*
27.0±0.19*
OHT, OAG
Feldman 200731) USA RCT brinzolamide + travoprost brimonidine + travoprost 84 79 163 64.00±10.25 2.91±9.34 22.2±0.34* 22.6±0.37* POAG, OHT
Feldman 201632) USA RCT BBFC + travoprost vehicle + travoprost 113 116 229 67.5±10.3 66.0±10.6 22.5±2.5 22.7±2.4 OAG, OHT
Holló et al. 200633) Multi-nations RCT brinzolamide + travoprost timolol + travoprost 97 95 192 63.9±11.7 62.2±10.4 22.3±2.6 22.6±2.8 POAG, OHT
Kaback 200834) USA RCT brinzolamide and timolol brinzolamide or timolol 171 173
173
517 N/A N/A 27.1±2.7 27.1±2.6
27.0±2.5
OHT, OAG
Nguyen 201335) USA RCT BBFC brinzolamide or brimonidine 218 229
232
679 65.7±10.3 64.2±10.3
64.9±10.5
27.2±2.8 27.2±2.7
27.3±2.7
OHT, OAG
Shin et al. 200036) USA RCT brinzolamide and timolol timolol 53 55 108 60.9±13.0 62.6±12.1 25.5±N/A 25.8± N/A OHT, OAG
Douglas et al. 200837) USA RCT brinzolamide and latanoprost brimonidine and latanoprost 20 20 40 57.5±14.1 60.0±11.6 21.0±3.32 30.4±2.62 OHT, OAG
Katz 201338) USA RCT brinzolamide and brimonidine brinzolamide or brimonidine 209 224
216
649 63.9±11.3 65.0±10.0
64.3±10.8
26.9±2.6 27.1±2.6
27.0±2.6
OHT, OAG

BBFC; brinzolamide and brimonidine fixed combination, BTFC; brinzolamide and timolol fixed combination, DTFC; dorzolamide and timolol fixed combination, RCT; randomized controlled trial, OH; ocular hypertension, OAG; open angle glaucoma, POAG; primary open angle glaucoma

*Baseline IOP [mean±SE, mmHg]

Korean J Clin Pharm 2021;31:205-15 https://doi.org/10.24304/kjcp.2021.31.3.205
© 2021 Korean J Clin Pharm